Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone216-431-9900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.29 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Athersys (NASDAQ:ATHX) Frequently Asked Questions
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) posted its quarterly earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company had revenue of $1.51 million for the quarter, compared to analysts' expectations of $0.55 million. Athersys had a negative net margin of 99.96% and a negative return on equity of 49.25%. View Athersys' Earnings History.
When is Athersys' next earnings date?
What price target have analysts set for ATHX?
1 Wall Street analysts have issued 1-year price objectives for Athersys' stock. Their predictions range from $8.00 to $8.00. On average, they anticipate Athersys' stock price to reach $8.00 in the next year. This suggests a possible upside of 409.6% from the stock's current price. View Analyst Price Targets for Athersys.
What is the consensus analysts' recommendation for Athersys?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athersys.
Has Athersys been receiving favorable news coverage?
Media coverage about ATHX stock has been trending somewhat positive on Thursday, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Athersys earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include Dicerna Pharmaceuticals (DRNA), Advanz Pharma (CXRXF), Principia Biopharma (PRNB), Radius Health (RDUS), Innovus Pharmaceuticals (INNV), Omeros (OMER), Y-mAbs Therapeutics (YMAB), Lexicon Pharmaceuticals (LXRX), Athenex (ATNX), Rocket Pharmaceuticals (RCKT), CymaBay Therapeutics (CBAY), Cara Therapeutics (CARA), ANI Pharmaceuticals (ANIP), Eidos Therapeutics (EIDX) and Revance Therapeutics (RVNC).
What other stocks do shareholders of Athersys own?
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)
- Mr. William B. J. Lehmann Jr., Pres, COO & Sec. (Age 53)
- Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)
- Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)
- Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs
Who are Athersys' major shareholders?
Athersys' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.33%), Geode Capital Management LLC (0.98%), Geode Capital Management LLC (0.98%), Northern Trust Corp (0.94%), Bank of America Corp DE (0.26%) and Alps Advisors Inc. (0.23%). Company insiders that own Athersys stock include John J Harrington, Laura K Campbell and William Lehmann Jr. View Institutional Ownership Trends for Athersys.
Which institutional investors are selling Athersys stock?
ATHX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Northern Trust Corp, California Public Employees Retirement System, NEXT Financial Group Inc and LPL Financial LLC. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell and William Lehmann Jr. View Insider Buying and Selling for Athersys.
Which institutional investors are buying Athersys stock?
ATHX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Alps Advisors Inc., Geode Capital Management LLC, Geode Capital Management LLC, Allred Capital Management LLC, Rhumbline Advisers and Two Sigma Securities LLC. View Insider Buying and Selling for Athersys.
How do I buy shares of Athersys?
Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of ATHX stock can currently be purchased for approximately $1.57.
How big of a company is Athersys?
Athersys has a market capitalization of $230.54 million and generates $24.29 million in revenue each year. The biopharmaceutical company earns $-24,280,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.
What is Athersys' official website?
How can I contact Athersys?
Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]
MarketBeat Community Rating for Athersys (NASDAQ ATHX)
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
